Literature DB >> 9702911

Effects of nebulized nitroprusside on pulmonary and systemic hemodynamics during pulmonary hypertension in piglets.

W Meadow1, B Rudinsky, A Bell, R Hipps.   

Abstract

We tested the effects of nebulized nitroprusside (Neb-NP) on pulmonary and systemic hemodynamics during pulmonary hypertension induced by hypoxia or group B streptococci infusion in piglets. Twenty-three anesthetized and mechanically ventilated piglets received Neb-NP under four experimental conditions: 1) normoxia; 2) 15 and 60 min of pulmonary hypertension induced by hypoxia; 3) after pretreatment with dipyridamole; 4) pulmonary hypertension induced by infusion of group B streptococci. In addition, Neb-NP was contrasted to nebulization of tolazoline. During hypoxia-induced pulmonary hypertension, Neb-NP significantly reduced pulmonary artery pressure [PAP; -8.4+/-0.9 (SEM) mm Hg] and pulmonary vascular resistance (-25+/-2.1%) (both p < 0.001), whereas neither systemic arterial pressure nor cardiac output changed significantly. Selective pulmonary vasodilation began within 2 min of the onset of Neb-NP, and did not wane over 1 h. In contrast, within 5 min after Neb-NP was discontinued while hypoxia persisted, PAP rose significantly. Pretreatment with dipyridamole did not enhance the pulmonary vasodilation induced by Neb-NP, but did reduce systemic arterial pressure. Nebulized tolazoline did not reduce PAP significantly, but did lower systemic arterial pressure. Selective pulmonary vasodilation induced by Neb-NP was significantly smaller during group B streptococci-induced versus hypoxia-induced pulmonary hypertension. In sum, Neb-NP produced prompt, significant, selective reduction of PAP in piglets with pulmonary hypertension. Cautious extrapolation of these findings to selected clinical conditions in human infants may be warranted.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9702911     DOI: 10.1203/00006450-199808000-00007

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  3 in total

Review 1.  Pharmacologic management of perioperative pulmonary hypertension.

Authors:  Julie W Cheng; Adriano R Tonelli; Gosta Pettersson; Richard A Krasuski
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

Review 2.  Inhaled therapy for the management of perioperative pulmonary hypertension.

Authors:  C A Thunberg; S T Morozowich; Harish Ramakrishna
Journal:  Ann Card Anaesth       Date:  2015 Jul-Sep

3.  Smooth muscle myosin inhibition: a novel therapeutic approach for pulmonary hypertension.

Authors:  David Ho; Li Chen; Xin Zhao; Nicquanna Durham; Malar Pannirselvam; Dorothy E Vatner; David J Morgans; Fady I Malik; Stephen F Vatner; You-Tang Shen
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.